Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 133.79% | -11.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 767.74% | -7.75% | |||
| Operating Income | -767.74% | 7.75% | |||
| Income Before Tax | -6,305.75% | 8.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6,307.15% | 8.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6,307.15% | 8.84% | |||
| EBIT | -767.74% | 7.75% | |||
| EBITDA | -768.93% | 7.73% | |||
| EPS Basic | -5,643.54% | 9.15% | |||
| Normalized Basic EPS | -654.83% | 9.04% | |||
| EPS Diluted | -5,643.54% | 9.15% | |||
| Normalized Diluted EPS | -654.83% | 9.04% | |||
| Average Basic Shares Outstanding | 11.56% | 0.33% | |||
| Average Diluted Shares Outstanding | 11.56% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||